Vycor Medical, Inc. Patent Portfolio Expands Further

Aug 16, 2011, 10:28 ET from Vycor Medical, Inc.

BOCA RATON, Fla., Aug. 16, 2011 /PRNewswire/ -- Vycor Medical, Inc. ("Vycor") announces that it has further strengthened its already robust patent portfolio, with the grant of a previously allowed patent and the allowance of three new patents. This brings the total number of worldwide allowed, granted or issued patents held by the Vycor Group to 20, with a further 31 patents pending.

The previously announced allowance for issuance for China Patent No. ZL200680056889.9 has been granted. This action provides Vycor patent rights with respect to its innovative ViewSite Brain Access System (VBAS) in China, a key strategic market for the Company. Vycor is in the closing stages of its China SFDA process which will enable it to commence sales of VBAS in China.

Three further patent allowances relate to Vycor Medical's NovaVision subsidiary.

  • Canada allowed the 2,475,042 patent application which is one of NovaVision's core groups of patents, which enables training in the intact visual field and also in the transition zone. This particular core group of patents is now allowed, granted or issued in every jurisdiction NovaVision applied.
  • The US allowed patent 2008/0024725 covering dynamic fixation. This establishes NovaVision's rights to include a "moving target" in a vision restoration therapy; this enables the stimulation of the motion-detecting visual pathways of a patent and will be an important feature in the next phase of product development.
  • Finally NovaVision's US 29/351,087 patent was allowed for issuance, which is a design patent for a perimeter controller.

These patent allowances and grants, together with those previously announced during the year, demonstrate the progress the Vycor Group is making to establish a firmly patent protected and valuable group of products and technologies.

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (OTC Bulletin Board: VYCO) is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective.  Vycor's innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community. Vycor is ISO 13485:2003 compliant, has FDA 510(K) clearance for brain and spine surgeries, CE Marking and HPB licensing in Canada. 

Vycor Medical's subsidiary NovaVision, Inc. researches, develops and provides science-driven light-based neurostimulation therapy and other medical technologies that help restore sight to patients with neurological vision impairments.  The company's proprietary, Visual Restoration Therapy (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury ("TBI"), or other acquired brain injury. VRT has FDA 510(K) clearance with patents granted in the US, Canada, and Europe. NovaVision also provides a device that aids in the early identification of visual field deficits: the Head Mounted Perimeter (HMP) - a portable and ADA-compliant instrument to aid in the detection and measurement of visual field deficits even in bed-ridden patients.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com or www.novavision.com.

Contact: Karen Coviello 561-558-2000 Kacoviello@novavision.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Vycor Medical, Inc.